Feed PRLD
PR

Prelude Therapeutics Incorporated

PRLD · NASDAQ

$3.96 +0.25% (+$0.01)
1M -29.29%
Market Cap $310.9M
P/E Ratio -
Div. Yield -
ROE 75.35%

Bulios Fair Price

$3.02

23.7% downside

Trenutna cena

$3.96

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica PRLD trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Moderate
4/9
Valuation
40 /100
Fair
P/S 13.86x
P/B 2.32x
P/E N/A
Growth
0 /100
Declining
Book val. growth 29.45%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak
Gross margin 98.26%
FCF margin 148.30%
Net margin 269.75%
Quality
2 /100
Poor
ROIC 43.74%
Asset turnover 0.12x
ROE 75.35%
Debt
100 /100
Low
Debt/Equity 0.13x
Current ratio 4.07x
Int. coverage N/A
Stability
77 /100
Stable
Beta 0.96x
Profitable years 0
EPS volatility 6.10%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o PRLD
Online

O podjetju

Prelude Therapeutics Incorporated (PRLD) is an American biopharmaceutical company focused on developing drugs for the treatment of cancer and other oncological diseases. Headquartered in Wilmington, Delaware, the company focuses on the discovery and development of small molecule inhibitors targeting specific signaling pathways and cellular mechanisms that are key to the growth and spread of cancer cells. Their research and development efforts are aimed at identifying and developing new drug compounds with the potential to provide new treatment options for cancer patients. Prelude Therapeutics seeks to leverage its deep understanding of the molecular mechanisms of cancer to create innovative therapeutic approaches and drugs with higher efficacy and lower side effects. Prelude Therapeutics Incorporated (PRLD) shares could be an attractive choice for investors following the biopharmaceutical sector and seeking investment opportunities in the research and development of drugs for oncological diseases.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Krishna Vaddi

Employees

79

Headquarters

Wilmington

Prihajajoči dogodki

11 NOV.

Earnings

Upcoming earnings report

42d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.